Tiziana Life Sciences (TLSA) announced that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients living with Multiple System Atrophy, MSA, at Brigham and Women’s Hospital in Boston, Massachusetts. The six-month open-label study will assess the potential of foralumab to reduce harmful neuroinflammation by engaging the body’s regulatory T cells through a novel, non-systemic delivery approach. Participants will receive treatment over eight dosing cycles, with the goal of determining whether this approach can slow disease progression and improve quality of life.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- FDA Approves Tiziana Life Sciences’ Phase 2a Trial for MSA
- Tiziana Life announces FDA approved IND for Phase 2a trial of foralumab
- Tiziana Life Sciences initiated with a Buy at Lucid Capital
- Tiziana Life Sciences Unveils Promising Alzheimer’s Treatment Findings
- Tiziana Life announces immunologic analysis of nasal foralumab in AD patients